PHAXIAM Therapeutics SA, formerly known as ERYTECH PHARMA SA, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The company relies on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics SA is developing a portfolio of phages targeting three of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
It offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 1.1K |
| Three Month Average Volume | 36.8K |
| High Low | |
| Fifty-Two Week High | 13 USD |
| Fifty-Two Week Low | 2.5 USD |
| Fifty-Two Week High Date | 15 May 2023 |
| Fifty-Two Week Low Date | 04 Mar 2024 |
| Price and Volume | |
| Current Price | 3.1 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | -18.04% |
| Thirteen Week Relative Price Change | -36.61% |
| Twenty-Six Week Relative Price Change | -41.39% |
| Fifty-Two Week Relative Price Change | -66.84% |
| Year-to-Date Relative Price Change | -34.92% |
| Price Change | |
| One Day Price Change | 0.00% |
| Thirteen Week Price Change | -31.27% |
| Twenty-Six Week Price Change | -32.61% |
| Five Day Price Change | 0.00% |
| Fifty-Two Week Price Change | -57.16% |
| Year-to-Date Price Change | -30.18% |
| Month-to-Date Price Change | 13.14% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 8.24417 USD |
| Book Value Per Share (Most Recent Quarter) | -99999.99 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 8.24242 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -99999.99 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -5.15618 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 2.33351 USD |
| Revenue Per Share (Trailing Twelve Months) | 1.92508 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | 0 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.08003 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -3.84699 USD |
| Normalized (Last Fiscal Year) | -5.2455 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.08003 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -3.84699 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.08003 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -3.84699 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 13.61813 USD |
| Cash Per Share (Most Recent Quarter) | -99999.99 USD |
| Cash Flow Per Share (Last Fiscal Year) | 1.54128 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -4.04942 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -99999.99 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -271.61% |
| Pretax Margin (Last Fiscal Year) | 4.41% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -42.06% |
| Operating Margin (Trailing Twelve Months) | -271.39% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -3.43% |
| Net Profit Margin (Trailing Twelve Months) | -209.75% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -58.00% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | 7.96% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -4.56% |
| EPS Change (Trailing Twelve Months) | -99,999.99% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -100,000 |
| Net Debt (Last Fiscal Year) | -27,467,800 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 3 |
| Price to Sales (Trailing Twelve Months) | 3 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 44 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -2 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 4 |
| Current Ratio (Most Recent Quarter) | -100,000 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -34,673,880 |
| Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -430 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 58 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -0.41% |
| Return on Assets (Trailing Twelve Months) | -99,999.99% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -0.98% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -0.56% |
| Return on Investment (Trailing Twelve Months) | -99,999.99% |
| Return on Investment (5 Year) | -99,999.99% |